Amgen registers Phase 3 MariTide trial against semaglutide in type 2 diabetesNov 6Weekly roundup, 4 itemsAmgenapremilastUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Amgen gets FDA biosimilar supplement approval for RIABNI; posts new evolocumab PK trialOct 2Weekly roundup, 5 itemsAmgenapremilastUpdated
Sign inSign in